Furthermore, the above effects have been proven to be due to the Rab23-mediacted expression inhibition of Gli1 and Gli2, suggesting Rab23 might be a potential therapeutic target for breast cancer (Liu et al. 2015). This evidence concerns the gene RAB23 and breast carcinoma.